ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ELDN vs CAMP // EV/EBITDA & P/E VALUATION

Eledon Pharmaceuticals Inc. (NASDAQ) VS. CAMP4 Therapeutics Corporation (NASDAQ) • 15-METRIC TALLY: ELDN 1 — CAMP 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELDN VS. CAMP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ELDN CAMP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — -12.19% — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 3/9 -2.00 CAMP /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 58.0 58.9 -0.90 CAMP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $247.0M $244.7M $2.3M ELDN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ELDN REV CAMP REV ELDN GROSS % CAMP GROSS % ELDN FCF CAMP FCF
FY 2025 $0 $3.5M — — -$62.3M -$29.8M
FY 2024 $0 $652.0K — — -$47.3M -$46.0M
FY 2023 $0 $350.0K — — -$39.5M -$44.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELDN // BETA —
CAMP // BETA —